公开(公告)号：US20210085652A1

公开(公告)日：2021-03-25

申请号：US17095327

申请日：2020-11-11

Applicant: Kowa Company, Ltd.

Inventor： Ryu Oshima ,  Gary Gordon

IPC: A61K31/423 ,  A61K9/00 ,  A61P9/04 ,  A61P3/10

Abstract: The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.

公开(公告)号：US20210077467A1

公开(公告)日：2021-03-18

申请号：US17099167

申请日：2020-11-16

Applicant: Kowa Company, Ltd.

Inventor： Ryu Oshima ,  Gary Gordon

IPC: A61K31/423 ,  A61K31/41 ,  A61K9/00 ,  A61K31/366 ,  A61K31/40 ,  A61K31/47 ,  A61K31/505 ,  A61K45/06

Abstract: The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.

公开(公告)号：US20210063768A1

公开(公告)日：2021-03-04

申请号：US17096718

申请日：2020-11-12

Applicant: KOWA COMPANY, LTD.

Inventor： Haruo Ishikawa

IPC: G02C7/02 ,  A61F2/16 ,  G02C7/04

Abstract: An ophthalmic lens has a cross-sectional shape in an arbitrary meridian direction on a lens surface of the ophthalmic lens. The cross-sectional shape is expressed by the following formula (1), Z = c  r 2 1 + [ 1 - c 2  r 2  ( k + 1 ) ] 1 / 2 + A  ( θ )  r 2 + B  ( θ )  r 4 . In the formula, c is a paraxial curvature of the ophthalmic lens, r is a distance from a lens center of the ophthalmic lens, k is a conic constant of a surface which is in rotation symmetry with respect to an optical axis of the lens in the ophthalmic lens. The variables c, r and k are used in common in the meridian direction on the lens surface, and A(θ) and B(θ) are parameters expressed by functions depending on an angle in the meridian direction.

公开(公告)号：US10932663B2

公开(公告)日：2021-03-02

申请号：US16210038

申请日：2018-12-05

Applicant: KOWA COMPANY, LTD.

Inventor： Satoshi Shimada ,  Takuya Hara

IPC: A61B3/00 ,  A61B3/024

Abstract: In a perimetry to be conducted, designating an inspection region through a region designator, a perimeter is configured to set a required time of the perimetry (upper limit time) through an upper limit condition setter and to determine total number or positions of stimulus presentation spots based upon the upper limit time. In such a configuration, an examinee knows the time to finish the inspection, and is able to highly keep his (her) concentration in comparison with a case where the required time is not known, thereby improving precision of the inspection.

公开(公告)号：US20200222370A1

公开(公告)日：2020-07-16

申请号：US16627061

申请日：2018-06-29

Applicant: KOWA COMPANY, LTD.

Inventor： Yuki KUROIWA ,  Akito MINAMIZONO

IPC: A61K31/423

Abstract: Provided is a pharmaceutical composition containing pemafibrate, a salt thereof or a solvate thereof and having excellent storage stability. The pharmaceutical composition is provided to contain pemafibrate, a salt thereof or a solvate thereof, wherein a pH value of a solution produced by dissolving or dispersing the pharmaceutical composition in water is 7 or more.

公开(公告)号：US20200046686A1

公开(公告)日：2020-02-13

申请号：US16609249

申请日：2018-06-29

Applicant: KOWA COMPANY, LTD.

Inventor： Satoshi KOJIMA ,  Ryohei TANIGAWA

IPC: A61K31/423 ,  A61P1/16

Abstract: To provide an appropriate method of treatment with pemafibrate for a liver cirrhosis patient.The present invention relates to the use of pemafibrate in a liver cirrhosis patient.More particularly, the present invention relates to a regimen for administering a reduced dose of pemafibrate to a liver cirrhosis patient in need of treatment with pemafibrate than to persons with normal liver function.

公开(公告)号：US20200038397A1

公开(公告)日：2020-02-06

申请号：US16566473

申请日：2019-09-10

Applicant: KOWA COMPANY, LTD.

Inventor： Yoshio KANEKO ,  Masayuki OHTA

IPC: A61K31/498 ,  A61P27/06 ,  A61K45/00 ,  A61K47/22 ,  A61K31/551

Abstract: A pharmacotherapy is provided for preventing glaucoma or preventing or treating ocular hypertension, the pharmacotherapy providing potent intraocular pressure-lowering action with fast-acting properties and prolonged duration. A combination of (S)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate of (S)−)-1-(4-fluoro-S-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or the salt thereof and an α2 agonist for preventing or treating glaucoma.

公开(公告)号：US10537579B2

公开(公告)日：2020-01-21

申请号：US15976135

申请日：2018-05-10

Applicant: JUNTENDO EDUCATIONAL FOUNDATION ,  KOWA COMPANY, LTD.

Inventor： Takenori Inomata ,  Toshinari Funaki

IPC: A61K31/551 ,  A61P27/02 ,  A61K9/08 ,  A61K9/00

Abstract: To provide a novel method for suppressing rejection after corneal transplantation.The method for suppressing rejection after corneal transplantation includes administering an effective amount of a Rho kinase inhibitor to a patient who needs it.

公开(公告)号：US20190342486A1

公开(公告)日：2019-11-07

申请号：US16474620

申请日：2018-01-30

Applicant: KOWA COMPANY, LTD.

Inventor： Tomohisa AZEGAMI

IPC: H04N5/232

Abstract: [Problem] To enable imaging to be performed with appropriate timing.[Solution] In a camera manipulation device 1 according to the present invention, a trigger signal T12 is issued and imaging is begun when a prescribed command is transmitted from a control circuit side to an imaging unit side (see S12). Because the issuance of such trigger signal T12 is not accepted before a character reception start command is issued, it is possible to perform imaging with appropriate timing.

公开(公告)号：US10413170B2

公开(公告)日：2019-09-17

申请号：US15107504

申请日：2014-12-22

Applicant: KOWA COMPANY, LTD.

Inventor： Satoshi Shimada ,  Takuya Hara

IPC: A61B3/024 ,  A61B3/00

Abstract: Through the present invention, a perimetry result is obtained for a position on a retina surface designated as a position to be tested. As illustrated in the drawing, “the position of a ganglion cell (RGC)” and “the position of a photoreceptor cell (C) for sending information to the ganglion cell (RGC)” are offset on the retina surface (macular part). Here, when position (P1) is designated as a test position for testing the functioning of a ganglion cell at position (P1), the perimeter of the present invention finds “the position (P2) of the photoreceptor cell for sending information to the ganglion cell at position (P1),” presents a visual target at position (P2) rather than position (P1), and tests a visual field. The information of the visual target is sent to the ganglion cell at position (P1), and the functioning of the ganglion cell can therefore be tested. The test result is correlated with the position (P1) and displayed, and the ganglion cell at the designated position (P1) can be therefore be tested.